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BACKGROUND: Atherosclerosis is a chronic inflammatory disease in 
part caused by lipid uptake in the vascular wall, but the exact underlying 
mechanisms leading to acute myocardial infarction and stroke remain 
poorly understood. Large consortia identified genetic susceptibility 
loci that associate with large artery ischemic stroke and coronary 
artery disease. However, deciphering their underlying mechanisms are 
challenging. Histological studies identified destabilizing characteristics in 
human atherosclerotic plaques that associate with clinical outcome. To 
what extent established susceptibility loci for large artery ischemic stroke 
and coronary artery disease relate to plaque characteristics is thus far 
unknown but may point to novel mechanisms.
METHODS: We studied the associations of 61 established cardiovascular 
risk loci with 7 histological plaque characteristics assessed in 1443 carotid 
plaque specimens from the Athero-Express Biobank Study. We also 
assessed if the genotyped cardiovascular risk loci impact the tissue-specific 
gene expression in 2 independent biobanks, Biobank of Karolinska 
Endarterectomy and Stockholm Atherosclerosis Gene Expression.
RESULTS: A total of 21 established risk variants (out of 61) nominally 
associated to a plaque characteristic. One variant (rs12539895, risk allele 
A) at 7q22 associated to a reduction of intraplaque fat, P=5.09×10−6 
after correction for multiple testing. We further characterized this 7q22 
Locus and show tissue-specific effects of rs12539895 on HBP1 expression 
in plaques and COG5 expression in whole blood and provide data from 
public resources showing an association with decreased LDL (low-density 
lipoprotein) and increase HDL (high-density lipoprotein) in the blood.
CONCLUSIONS: Our study supports the view that cardiovascular 
susceptibility loci may exert their effect by influencing the atherosclerotic 
plaque characteristics.
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Atherosclerosis refers to the lifelong process of lesion formation and progression in the inner linings of arteries1 and underlies coronary artery 
disease (CAD) and large artery ischemic stroke (LAS).2 
CAD and LAS are complex diseases with a shared ge-
netic architecture.3,4 To date, meta-analyses of genome-
wide association studies (GWAS) identified multiple 
genetic loci for CAD5 and 4 for LAS.6–8 Despite this 
progress, it has proven challenging to interpret these 
findings in terms of the underlying biological mecha-
nisms or to formulate testable therapeutic hypotheses.
Histological analyses of atherosclerotic plaques have 
provided insight into the process of atherosclerosis.1 
The high-risk lesion characterized by variability in lip-
id, inflammatory, calcific, and thrombotic components 
is prone to destabilization and rupture,1,9,10 resulting 
in acute cardiovascular disease.10–13 But the extent to 
which common sequence variation that associates to 
CAD and LAS risk also relates to advanced destabilizing 
atherosclerotic lesion characteristics remains unclear.
The Athero-Express (AE) Biobank Study,9 STAGE 
(Stockholm Atherosclerosis Gene Expression),14 and 
BiKE (Biobank of Karolinska Endarterectomy)15,16 are 3 
independent, deeply phenotyped biobank studies com-
prising individuals undergoing surgical interventions. 
The AE assesses the genetic architecture of histological-
ly analyzed plaque specimens and plaque-derived DNA 
methylation. STAGE and BiKE focus on the genetics of 
tissue-specific differential gene expression.
Here we specifically investigated the association of 
61 established susceptibility loci for CAD and LAS to 
plaque characteristics in the AE study. We find that 
these risk loci are broadly albeit nominally associated 
with human atherosclerotic plaque characteristics. We 
report that the risk allele (A) of 1 variant (rs12539895) 
on chromosome 7q22 near COG5 and HBP1 was sig-
nificantly associated with a reduction in intraplaque 
fat (P=5.09×10−6 after correction for multiple testing). 
To further increase our understanding of this associa-
tion, we investigated the effects of common variants 
at 7q22 on carotid plaque DNA methylation and tissue-
specific gene expression, by combining data from the 
AE, STAGE, and BiKE studies.
METHODS AND MATERIAL
This study complies with the Declaration of Helsinki, and all 
participants provided informed consent. The medical ethical 
committees of the respective hospitals approved these studies.
The data, analytic methods, and study materials will be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure. The raw omics 
data are available through the European Genome-Phenome 
Archive. The main scripts used for the quality control and 
the (meta-)analysis of the data are available through GitHub 
(https://github.com/swvanderlaan/publications under doi: 
10.5281/zenodo.1069531).
The Methods and Material can be found in the Data 
Supplement.
RESULTS
Clinical Characteristics of the 3 Cohorts
For this study, we included individuals from 3 indepen-
dent biobank studies, the AE,9 BiKE,15,16 and STAGE.14 
Each study included patients with clinically significant 
arterial stenosis that are similar at baseline (Table 1).
Single-Variant Analysis of CAD and LAS 
Associated Loci With Plaque Characteristics
In the AE we correlated 61 established susceptibility loci 
for CAD and LAS5–8 to commonly assessed plaque char-
acteristics; 5 Loci identified in a GWAS for bipolar dis-
order17,18 served as negative controls (these 66 variants 
are listed in Table I in the Data Supplement). There were 
21 (out of 61) cardiovascular risk alleles nominally asso-
ciated with plaque characteristics and 0 (out of 5) bipo-
lar disorder associated variants (at a nominal P<0.05; 
Tables 2 and 3).
One variant (rs12539895) significantly associated 
with a reduction of intraplaque fat after correction for 
multiple testing, with a per A-allele odds ratio=0.63, 
95% CI, 0.51–0.77; P=5.09×10−6 (Table  3; Figure  1). 
This intronic single-nucleotide variant is located on 
chromosome 7q22 in the gene encoding for conserved 
oligomeric Golgi complex subunit 5 (COG5). Overall, 
intraplaque fat was the plaque characteristic that was 
the most commonly associated with CAD risk loci (6 out 
of 21 with a nominal P<0.05).
CAD loci also nominally associated with athero-
sclerotic plaque collagen content, smooth muscle cell 
(SMC) percentage, the percentage of macrophages, 
the extent of calcification, intraplaque hemorrhage, 
and intraplaque vessel density (Tables  2 and 3). Two 
LAS susceptibility loci (near TSPAN2 on 1p13.2 and 
rs556621 on 6p21.1) nominally associated with intra-
plaque calcification and SMCs, respectively.
As expected, none of the negative control bipolar 
disorder risk-variants associated with any of the plaque 
characteristics.
Gene-Based Analysis of CAD and LAS 
Associated Loci With Plaque Characteristics
We mapped 787 genes to the 66 loci and applied gene-
based association tests using VEGAS2 (Versatile Gene-
based Association Study 2)21,22 on the 7 measured plaque 
characteristics (Material in the Data Supplement). One 
gene, HMG-box transcription factor 1 (HBP1), on chro-
mosome 7q22 significantly associated with intraplaque 
fat (P=9.0×10−7 corrected for 7 traits and 787 genes, 
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Table II in the Data Supplement). Consistent with this 
result, the top single-nucleotide variant in HBP1 identi-
fied by VEGAS2, rs10953530 (odds ratio=1.63, 95% 
CI, 1.33–2.00 per A-allele, P=1.84×10−6; Table II in 
the Data Supplement), is in strong LD (r2=0.90) with 
rs12539895, the top association signal in COG5.
Tissue-Specific Effects of Cardiovascular 
Risk Loci on Gene Expression in STAGE and 
BiKE
Given the single-variant and gene-based association 
presented above, we further explored the 7q22 locus 
Table 1. Clinical Characteristics of the AE, BiKE, and STAGE
Characteristic
AE BiKE STAGE
n=1439 n=127 n=109
Male, N (%) 977 (67.89) 100 (78.74) 98 (90.00)
Age, y (SD) 68.79 (9.31) 70.56 (8.90) 65.90 (8.00)
History, N (%)
  Cerebrovascular disease 1184 (82.28) 101 (79.53) 9 (8.00)
  Coronary artery disease 429 (29.81) 26 (20.47) 100 (91.74)
  Peripheral arterial disease 251 (17.44) n/r n/r
Risk factors
  Type 2 diabetes mellitus 332 (23.07) 32 (25.20) 24 (22.00)
  Hypertension 1231 (85.55) 106 (83.46) 70 (64.00)
  Current smoker 492 (34.19) 61 (48.03) 7 (6.00)
  BMI 25.95 (24.02–28.39) 26.44 (23.70–28.40) 25.93 (23.66–28.19)
  eGFR 72.26 (58.79–85.38) n/r 55.36 (48.02–62.70)
  TC 4.64 (3.84–5.50) 4.30 (3.70–5.22) 3.94 (3.24–4.63)
  LDL 2.70 (2.03–3.40) 2.30 (1.90–3.00) 2.00 (1.46–2.53)
  HDL 1.11 (0.90–1.38) 1.10 (0.90–1.30) 1.45 (1.28–1.62)
  TG 1.40 (1.00–2.00) 1.45 (1.00–2.12) 1.23 (0.85–1.60)
Medication, N (%)
  Antihypertensives 1104 (76.72) 110 (86.61) 96 (88.00)
  LLDs 1112 (77.28) 106 (83.46) 13 (12.00)
  Antithrombotics 1272 (88.39) 29 (22.83) 93 (85.00)
Symptoms, N (%)
  Asymptomatic 195 (13.55) 40 (31.50) n/r
  Ocular 221 (15.36) 25 (19.68) n/r
  TIA 635 (44.13) 27(21.26) n/r
  Stroke 383 (26.62) 32 (36.78) n/r
Surgery, N (%)
  De novo 1363 (94.72) n/r n/r
  Restenosis 46 (3.20) 2002 n/r
  Period, y 2002–2013 2002 2009
For more details, refer to Material and Methods section. Cerebrovascular disease history includes ischemic stroke 
and TIA. Coronary artery disease history includes coronary artery disease, myocardial infarction, percutaneous 
coronary intervention, and coronary artery bypass graft. Peripheral disease history includes diagnosed peripheral 
arterial occlusive disease, femoral artery interventions, and ankle-brachial index <70. Type 2 diabetes mellitus and 
hypertension include all individuals with diagnosed type 2 diabetes mellitus or hypertension, respectively, and those 
on appropriate medication. Current smokers include all individuals smoking up to 6 mo until the surgery date. BMI, 
kg/m2. eGFR rate was based on the Modification of Diet in Renal Disease formula, mL/min per 1.73 m2. All lipids 
are in mmol/L. Antihypertensives include all antihypertension medication. Antithrombotics include clopidogrel, 
dipyridamole, acenocoumarin, ascal, and anti-platelet drugs. Carotid symptoms are the symptoms before surgery, 
which are the indication for surgery. Surgery includes de novo stenotic arteries, or re-stenotic arteries (restenosis), and 
the surgery period (in y) is indicated. Categorical risk factors are noted in N (%), continuous risk factors are in median 
(IQR) unless otherwise indicated. AE indicates Athero-Express; BiKE, Biobank of Karolinska Endarterectomy; BMI, body 
mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, 
low-density lipoprotein; LLDs, lipid-lowering drugs including statins and other lipid-lowering drugs; STAGE, Stockholm 
Atherosclerosis Gene Expression; TC, total cholesterol; TG, triglycerides; and TIA, transient ischemic attack.
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with respect to regional gene regulation and expres-
sion. Genetic variants could regulate gene expression 
by altering transcription factor binding or splice sites 
in plaques or other relevant tissues; such variants are 
known as expression quantitative trait loci. We asso-
ciated variants in 7q22 with regional gene expression 
in diseased tissues from the STAGE and BiKE studies 
and tissues from the general population in the public 
Genotype-Tissue Expression project.23
In STAGE, the rs12539895 associated with a reduc-
tion of COG5 expression in atherosclerotic arterial wall 
tissue, internal mammary artery, and whole blood (Table 
III in the Data Supplement). Overall, 21 variants associ-
ated with expression of 10 genes across 6 tissues at a 
false-discovery rate Q≤0.05; most expression quantita-
tive trait loci were found in liver and whole blood tissue 
(Figure I in the Data Supplement).
In BiKE 3 correlated variants significantly associated 
with an increase of HBP1 expression in carotid plaques, 
P=7.0×10−6; these are proxies for rs12539895 (LD 
r2>0.90; Figure  2; Table IV in the Data Supplement). 
The same alleles decrease CAD risk and intraplaque fat 
(Table IV in the Data Supplement). Given the association 
of rs12539895 with reduced intraplaque fat and the 
central role of the LDL (low-density lipoprotein) recep-
tor (encoded by LDLR) in lipid uptake, we investigated if 
regional gene expression correlated to LDLR expression 
in carotid plaques from BIKE. Indeed, carotid plaque 
Table 2. CAD and LAS Susceptibility Loci and Their Association With Quantitative Plaque Phenotypes
Phenotype Locus Variant Chromosomal BP Alleles CAF β (SEM) P Value Disease GWAS Dir.
Macrophages BCAS3 rs7212798 17 59,013,488 C/T 0.154 −0.137 (0.054) 0.011 CAD −
SMCs LIPA rs1412444 10 91,002,927 T/C 0.363 0.083 (0.040) 0.036 CAD −
COL4A1/A2 rs11838776 13 111,040,681 A/G 0.261 0.103 (0.042) 0.015 CAD −
Vessel density SWAP70 rs10840293 11 9,751,196 A/G 0.569 0.079 (0.040) 0.046 CAD +
KSR2 rs11830157 12 118,265,441 G/T 0.395 0.109 (0.040) 6.97×10−3 CAD −
UBE2Z rs46522 17 46,988,597 T/C 0.540 −0.080 (0.038) 0.034 CAD −
SMCs 6p21.1 rs556621 6 44,594,159 G/T 0.698 0.101 (0.041) 0.015 LAS −
Per variant the reported locus, the chromosomal BP, the effect and other allele (Alleles), as well as the CAF is given. For each variant the effect size (β)±SEM 
is relative to the coded allele with its P value of association with the quantitative plaque phenotype. Also indicated is the disease (CAD or LAS) to which the 
respective variant was originally associated in the GWAS. Additional per variant statistics are in Table I in the Data Supplement. BP indicates base pair position; 
CAD, coronary artery disease; CAF, coded allele frequency; GWAS, genome-wide association study; GWAS Dir., the direction of effect in the CAD GWAS; LAS, 
large artery stroke; and SMCs, smooth muscle cells.
Table 3. CAD and LAS Susceptibility Loci and Their Association With Semi-Quantitative Plaque Phenotypes
Phenotype Locus Variant Chromosomal BP Alleles CAF OR (95% CI) P Value Disease GWAS Dir.
Calcification WDR12 chr2:203828796:I 2 203,828,796 CTA/C 0.126 0.74 (0.58–0.94) 0.012 CAD +
ZNF259-APOA5-
APOA1
rs964184 11 116,648,917 C/G 0.861 1.26 (1.01–1.58) 0.043 CAD +
LDLR rs56289821 19 11,188,247 A/G 0.106 1.59 (1.21–2.07) 6.29×10−4 CAD −
KCNE2 (gene 
desert)
rs28451064 21 35,593,827 A/G 0.114 0.71 (0.55–0.91) 7.92×10−3 CAD −
Collagen NOS3 rs3918226 7 150,690,176 T/C 0.076 1.73 (1.03–2.90) 0.031 CAD −
SMG6 rs216172 17 2,126,504 C/G 0.330 0.78 (0.64–0.95) 0.012 CAD −
Intraplaque 
fat
MIA3 rs67180937 1 222,823,743 G/T 0.715 1.27 (1.02–1.56) 0.029 CAD +
ZEB2-
ACO74093.1
rs17678683 2 145,286,559 G/T 0.088 1.38 (1.00–1.92) 0.049 CAD −
7q22 rs12539895 7 107,091,849 A/C 0.234 0.63 (0.51–0.77) 5.09×10−6 CAD −
NOS3 rs3918226 7 150,690,176 T/C 0.076 1.73 (1.03–2.90) 0.031 CAD +
TRIB1 rs2954029 8 126,490,972 T/A 0.475 0.77 (0.65–0.92) 3.54×10−3 CAD −
ABO rs2519093 9 136,141,870 T/C 0.199 1.27 (1.02–1.59) 0.034 CAD −
IPH LIPA rs1412444 10 91,002,927 T/C 0.362 1.27 (1.07–1.52) 6.33×10−3 CAD −
Calcification TSPAN2 (1p13.2) rs12122341 1 115,655,690 G/C 0.257 1.19 (1.00–1.43) 0.048 LAS +
Per variant the reported locus, the chromosomal BP, the effect and other allele (Alleles), as well as the CAF is given. The OR±95% CI is relative to the risk 
allele with its associated P value. Also indicated is the disease (CAD or LAS) to which the respective variant was originally associated in the GWAS. Additional 
per variant statistics are in Table I in the Data Supplement. Intraplaque fat, as <10% vs >10% fat per the total plaque area. BP indicates base pair position; CAD, 
coronary artery disease; CAF, coded allele frequency; GWAS, genome-wide association study; GWAS Dir., indicates the direction of effect in the CAD GWAS; IPH, 
intraplaque hemorrhage; LAS, large artery stroke; and OR, odds ratio.
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expression of PRKAR2B, COG5, DUS4L, and CBLL1 was 
significantly correlated to LDLR expression (P<4.6×10−3 
after correction for 11 genes tested; Table V in the Data 
Supplement).
Tissue-Specific Effects of Cardiovascular 
Risk Loci on Gene Expression in the 
General Population
In contrast, data from the Genotype-Tissue Expres-
sion project, comprising 48 pathology tissues of indi-
viduals from the general population, indicates that 
rs12539895 only associates to increased expression 
HBP1 in testis, sun-exposed skin of the lower leg, and 
tibial artery (Table VI in the Data Supplement) and 
increased expression of BCAP29 in lung tissues. In addi-
tion, proxies of rs12539895 (LD r2>0.80) associate with 
differential expression in tibial nerves, skeletal muscle 
cells, sigmoid colon, and basal ganglia (Table VI in the 
Data Supplement).
Tissue-Specific Sequence Variation 
Effects on Methylation
Sequence variation may regulate gene expression indi-
rectly through changes in DNA methylation at sites 
rich of cytosine-guanine dinucleotides (CpGs) and in a 
tissue-specific manner.24 To uncover cis-acting methyl-
ation quantitative trait loci we associated genetic vari-
ants in 7q22 with the methylation of CpGs mapped 
to the same region in plaques from the AE. A perfect 
proxy for rs12539895, rs80341862, was significantly 
associated with a decrease in methylation of a CpG 
at the 3´ UTR of COG5 and HBP1 (false discovery rate 
Figure 1. Associations of genetic variants in 7q22 with carotid intraplaque fat.  
Rs12539895 was previously associated with coronary artery disease (CAD; purple). The strongest association was for a deletion chr7:106901393 (triglycerides [TG] 
>T; P=2.14×10−7; pink). The x axis shows the chromosomal position relative to 1000G (March 2012, Hg19). The lower shows refSeq canonical genes from UCSC 
(the black arrow indicates the direction of transcription). The left y axis shows the −log10(P value) of the association with intraplaque fat. The right y axis shows 
the recombination rate (gray line in the middle). The middle shows each associated variant colored by the r2 relative to rs12539895. The legend in the upper 
right corner shows the r2 color scale. The per variant annotation key is depicted in the bottom left corner. Made using LocusZoom version 1.3 and SNiPA.19,20 
COG5 indicates component of oligomeric Golgi complex 5; CpG, cytosine-guanine dinucleotide; eQTL, expression quantitative trait loci; HBP1, HMG-box transcrip-
tion factor 1; and mQTL, methylation quantitative trait loci.
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Q value=5.41×10−9 after 1000 permutations; Table 
VII in the Data Supplement). However, the decreased 
methylation of this CpG (cg24556660) did not cor-
relate to intraplaque fat (odds ratio=0.98, 95% CI, 
0.92–1.05; P=0.62).
COG5 and HBP1 Are Expressed in Carotid 
Plaques
Although it is clear that COG5 and HBP1 are expressed in 
various tissues (Tables IV and VI in the Data Supplement), 
no data exist on spatial distribution in atherosclerotic 
lesions. We investigated the spatial localization in carotid 
plaques from the AE using immunohistochemistry spe-
cific for COG5 (component of oligomeric Golgi complex 
5) and HBP1 (HMG-box transcription factor 1; Figure II in 
the Data Supplement). Figure III in the Data Supplement 
shows that COG5 is expressed in most cells in plaques, 
whereas HBP1 is expressed primarily in cells with a foam-
cell like morphology (Figure IV in the Data Supplement).
Cardiovascular Risk Factors and the 7q22 
Locus
The dominant causal contributing factors for cardio-
vascular disease risk are circulating lipid proteins, pre-
sumably leading to changes in intraplaque fat. As the 
intraplaque fat and CAD associated alleles correlate 
with gene expression in relevant tissues for lipid metab-
olism (liver) and atherosclerosis (carotid plaques, arte-
rial wall tissues, and whole blood), we speculated that 
these variants may associate to circulating blood lipid 
levels too. Indeed, data from the Global Lipids Genetics 
Consortium25 revealed that the risk-reducing allele of 
rs12539895 also associated with a decrease in circu-
lating LDL and an increase in HDL (high-density lipo-
protein) but not with other cardiovascular risk factors 
(Table VIII in the Data Supplement).
Polygenic Association of Clinically 
Relevant Variants With Plaque Phenotypes
Because of the central role of atherosclerosis in CAD 
and LAS and the presumed polygenic nature of these 
complex diseases, we further tested the contribution 
of modestly associated variants, ascertained through 
GWAS, on atherosclerotic characteristics. We summed 
genetic variation weighted by the effect on disease risk 
into polygenic risk scores.18 We made polygenic scores 
using imputed genotype data from AE and the allelic 
effects estimated through GWAS on CAD and LAS (Table 
IX in the Data Supplement); each score included variants 
selected by using increasingly liberal thresholds of sig-
nificance (PT; Table X and Figure V in the Data Supple-
ment).18 We then correlated each of these scores, which 
capture the effects of individual variants on clinical out-
come, to the atherosclerotic plaque phenotypes. We 
found significant associations for the CAD score with 
intraplaque fat, while the LAS score was associated with 
intraplaque hemorrhage and SMCs (Figure 3; P<0.05).
Figure 2. Association of rs3815148 with HBP1 expression in carotid plaques.  
Rs3815148 is a proxy (LD r2=0.91) for rs12539895 and associated (P=7.0×10−6) with HBP1 expression in carotid plaques from BiKE. A, Regional association of 
variants with HBP1 expression in carotid plaques. The x axis shows the chromosomal position relative to 1000G (March 2012, Hg19) and refSeq canonical genes 
(green) from UCSC (the black arrow indicates the direction of transcription). The left y axis shows the −log10 P value of the association with HBP1 expression. The 
right y axis shows the recombination rate (gray line). The middle shows each associated variant colored by the r2 relative to rs12539895. The legend in the upper 
right corner shows the r2 color scale. B, Boxplot of the association of rs3815148 with HBP1 expression. Proxy data based on 1000G phase 3, version 5 data from 
SNiPA.20 Made using LocusZoom version 1.3.19
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DISCUSSION
In this study, we show that 21 out of 61 established 
cardiovascular genetic risk loci nominally associ-
ated to human plaque characteristics. One variant 
(rs12539895 at 7q22) significantly associated with 
a reduction of fat in carotid plaques. Tissue-specific 
expression analyses revealed effects of this variant 
on COG5, and HBP1, expression in arterial wall tis-
sue, internal mammary artery, carotid plaques, and 
whole blood tissues, as well as differential methyla-
tion in carotid plaques. In human plaques, COG5 is 
ubiquitously expressed (Figure III in the Data Supple-
ment), while HBP1 is concentrated near foam-like cells 
(Figure IV in the Data Supplement). Last, in line with 
the current understanding of the role of lipids in car-
diovascular disease, rs12539895 also associates with 
a decrease in circulating LDL and an increase in HDL.
The polygenic score analyses showed the strongest 
correlation of a CAD polygenic score with intraplaque 
fat. In contrast, polygenic scores for LAS associated 
with intraplaque hemorrhage and SMCs.
The second strongest association was with calci-
fication (rs56289821 near LDLR). Indeed, disruption 
of the LDLR pathway has been implicated in arterial 
calcification in mice26 and aortic valve calcification in 
humans with a mutation in LDLR.27 A further notable 
result involves a variant (rs2954029) near TRIB1, which 
was associated with a reduction of intraplaque fat. The 
T-allele of this variant was previously associated with 
a decrease in circulating triglycerides, LDL cholesterol, 
and ApoB (Apolipoprotein B), and an increase in HDL.28 
The same study also showed a decreased risk for isch-
emic heart disease and myocardial infarction.
We also note that some variants show directions of 
effects on plaque characteristics opposite to the direction 
observed in GWAS for primary disease risk. For instance, 
the risk allele A of rs11838776 near COL4A1/A2 asso-
ciates with more SMCs (Table 2) but is correlated to a 
reduction in CAD risk. This suggests that rs11838776 
is reducing overall CAD risk, possibly through an overall 
increase in SMCs, in some individuals more (those carry-
ing the risk allele) than others. Such paradoxical findings 
may point to potentially interesting biological mecha-
nisms that need further scrutiny in future studies.
Given that rs12539895 at 7q22 was the only variant 
significantly associated to a plaque characteristic (intra-
plaque fat) after correction for multiple testing, we fur-
ther explored this locus. Strong LD between variants 
extends between 106.7 and 107.2 Mb in this locus (Fig-
ure 1), complicating the identification of causal gene(s). 
However, our results converge around only a few genes 
at 7q22: in particular HBP1 and COG5. The CAD risk 
associated variant rs12539895 associates with COG5 
and HBP1 gene expression in relevant tissues with direc-
tionally consistent effects. Thus, although the current 
study is unable to point to the causal gene, it prioritizes 
the above genes.
HBP1 is a transcriptional repressor binding to pro-
moter regions, it plays a role in Wnt1 signaling29 and 
cancer30,31, and is mostly expressed in the heart. In a 
rat model of carotid injury therapeutic inhibition of 
HBP1 (known as Hmgb1 in rodents) was associated 
with a decrease in vascular SMC activation and neo-
intimal formation.32 Another study showed that HBP1 
is targeted by miR-155.33 Inhibition of miR-155 atten-
uated foam cell formation and reduced atheroscle-
rotic plaques in ApoE−/− mice, and HBP1 knockdown 
Figure 3. Polygenic scores of coronary artery disease (CAD; dark pink) and large artery stroke (LAS; blue) associate with different plaque characteristics.  
Polygenic scores for CAD associate with intraplaque fat (A), whereas polygenic scores for LAS associate with intraplaque hemorrhage (B) and smooth muscle cells (C). 
Scores were constructed based on GWAS (Genome-Wide Association Study) summary statistics using increasingly liberal P value thresholds (PT, see also Information 
in the Data Supplement; Table II in the Data Supplement). Each PT bin is depicted on the x axis. The y axis indicate the r
2 of the association; please note the different 
scales. *P<0.05 for association of the score with the plaque characteristic. PGC indicates bipolar disorder from the Psychiatric Genetics Consortium (green).
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enhanced lipid uptake by macrophages.33 Our expres-
sion quantitative trait loci analyses in BiKE provide 
confirmation of these results in humans, as the risk-
reducing allele of rs12539895 proxies increase HBP1 
expression in carotid plaques (Figure 2; Table IV in the 
Data Supplement).
COG5 has not been associated with atherosclerotic 
disease previously. COG5 is part of an evolutionary 
conserved protein complex in the Golgi apparatus that 
is involved in protein and lipid trafficking and sort-
ing.34 It plays a major role in glycosylation of proteins. 
One report discusses a mutation near the 3´ UTR of 
COG5 leading to impaired glycosylation of proteins, 
one of which was ApoC-III.35 Another study reported 
that COG5 depletion in HeLa cells did not significantly 
affect glycosylation or membrane expression of LDLR.36 
Strikingly, COG5 knockdown in these cells leads to a 
significant dilation of Golgi-apparatus cisternae, as 
well as an impaired intracellular trafficking leading to 
an accumulation of intracellular LDLR.36 In this study, 
we show that COG5 expression negatively correlates 
with LDLR expression in human carotid plaques. The 
CAD risk-reducing allele of rs80341862 (a rs12539895 
proxy) associated with decreased COG5 expression in 
atherosclerotic arterial wall, internal mammary artery 
tissue, and whole blood tissues (Table III in the Data 
Supplement), and reduced intraplaque fat (Table  3). 
Although this variant associated with a decreased 
methylation at the 3´ UTR of COG5 in plaques (Table 
V in the Data Supplement), the methylation itself did 
not associate with the prevalence of fat in plaques. 
This indicates a direct effect on transcription through 
sequence variation rather than through gene regula-
tion by methylation.
Our tissue-specific transcriptional analyses are con-
sistently showing effects of rs12539895 and its proxies 
on HBP1 and COG5 in (atherosclerotic) arterial wall tis-
sues. Interestingly, only HBP1 was expressed in arterial 
wall tissue from Genotype-Tissue Expression, poten-
tially indicating a tissue-specific effect on HBP1, and a 
disease-specific effect on COG5.
Furthermore, 2 studies tied variants (rs381514837 
and rs473025038) at 7q22 to susceptibility of osteoar-
thritis and pointed to COG5 and DUS4L as potential 
causal candidates; these variants are in high LD with 
rs12539895 (r2>0.80). In turn, osteoarthritis is associ-
ated with carotid intima-media thickness,39 a proxy of 
atherosclerosis severity, and circulating cholesterol.40 In 
point of fact, some have speculated that a transition 
of chondrocytes to a foam-cell like morphology may 
be responsible to osteoarthritis.40 Other GWAS also 
pointed to variants at 7q22 and mapped PIK3CG as 
potentially causal for ulcerative colitis,41 systolic blood 
pressure,42 mean platelet volume,43 carotid plaque pres-
ence, and carotid intima-media thickness.44 While none 
of the variants near PIK3CG are in LD with rs12539895, 
of note is the fact that rs17398575, associated to 
plaque presence and carotid intima-media thickness, 
is an expression quantitative trait loci in aorta for 
PRKAR2B near HBP1.23 Last, a large-scale genetic analy-
sis of serum metabolite levels associated rs12539895 
to lower levels of 10-undecenoate (11:1n1)/X-11438. 
However, these are speculations and strong evidence 
linking carotid intima-media thickness, osteoarthritis, 
and our findings have yet to be provided.
The association of 7q22 with circulating lipids, 
rather than other cardiovascular risk factors, implicates 
a role for lipid metabolism that may lead to reduced 
intraplaque fat and a reduction in CAD risk. Last, our 
histological analyses indicate a role for HBP1 with a 
foam-like appearance in carotid plaques (Figure IV in 
the Data Supplement), but more specific staining, for 
example, for oxidized LDL scavenger receptors, are 
needed to determine the type of cells.
The lack of association for the 40 other cardiovascu-
lar risk variants may indicate mechanisms in play that are 
not capture by our histological measurements. However, 
some variants may simply not exert their effect through 
atherosclerosis directly but rather through changes in 
for example cardiac tissue and thereby modulate risk. 
Finally, we have studied the association of these vari-
ants with plaques at the end stage of atherosclerotic 
disease, thus we cannot exclude that a causal role in 
early plaque development.
Admittedly, these observations require confirma-
tion, and reducing the noise in histological phenotype 
measurements through alternative methods might be a 
feasible way to increase power.45,46 Also, our measure 
of intraplaque fat is an overall measure of intraplaque 
fat as described by Verhoeven et al9; thus we cannot 
ascertain which fraction of lipids and which cells might 
be involved. Power may have impeded our polygenic 
score analyses, as well as the identification of CpGs 
associating with intraplaque fat. We were also unable 
to directly test tissue-specific gene expression to intra-
plaque fat; thus, further studies are needed to explore 
this. Still, although sample size and some phenotypic 
heterogeneity limit our power, the size and scope of 
the AE are unique (in its kind) and allow for the most 
in-depth study of genetic variation with human plaques 
characteristics to date.
In conclusion, our study supports the view that car-
diovascular susceptibility loci may exert their effect by 
influencing the atherosclerotic plaque characteristics. 
Further functional studies will be needed to test the 
hypothesis that HBP1 and COG5 are indeed linked to 
atherosclerosis and specific plaque characteristics.
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